Published: 4 March 2024
Author(s): Fotios Barkas, Evangelos Liberopoulos, Manfredi Rizzo
Issue: May 2024

Familial hypercholesterolaemia (FH) is the most encountered inherited metabolic disorder and is associated with premature cardiovascular disease.[1] Although early diagnosis is imperative for initiating timely lipid-lowering therapy and preventing atherosclerosis, most individuals with FH are undiagnosed, and treatment is often suboptimal even in the case of a definite diagnosis.[2,3] FH diagnosis involves a combination of clinical and genetic criteria [1], but their interplay can be intricate. Indeed, clinical manifestations might not align with causative variants, or clinically suspected FH may not be associated with causative variants.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.